Holen Sie sich die Stockscreener-App
0.4115
7.42%
-0.033
Handel nachbörslich:
.40
-0.0115
-2.79%
Schlusskurs vom Vortag:
$0.4445
Offen:
$0.439
24-Stunden-Volumen:
213.00K
Relative Volume:
0.43
Marktkapitalisierung:
$11.86M
Einnahmen:
$16.77M
Nettoeinkommen (Verlust:
$-11.87M
KGV:
-0.6573
EPS:
-0.626
Netto-Cashflow:
$-5.90M
1W Leistung:
-8.09%
1M Leistung:
-23.80%
6M Leistung:
-65.13%
1J Leistung:
-69.52%
1-Tages-Spanne:
$0.392
$0.4765
1-Wochen-Bereich:
$0.392
$0.53
52-Wochen-Spanne:
$0.3503
$2.60
Immunoprecise Antibodies Ltd Stock (IPA) Company Profile
Firmenname
Immunoprecise Antibodies Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie IPA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| IPA | 0.4115 | 11.86M | 16.77M | -11.87M | -5.90M | -0.626 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Immunoprecise Antibodies Ltd Stock (IPA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-12-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-25 | Eingeleitet | The Benchmark Company | Buy |
Immunoprecise Antibodies Ltd Aktie (IPA) Neueste Nachrichten
ImmunoPrecise's Breakthrough Cancer Treatment Shows Promise in $20.7B ADC Market | IPA Stock News - StockTitan
Immunoprecise Antibodies Ltd (IPA-Q) QuotePress Release - The Globe and Mail
ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation - BioSpace
ImmunoPrecise Pummeled Despite Advancing Anti-Aging Research with Mayo - Baystreet.ca
ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology - Business Wire
ImmunoPrecise Antibodies Announces Annual Meeting Plans - TipRanks
ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024 - BioSpace
ImmunoPrecise touts potential of rabbit monoclonal antibodies in oncology - Pharmaceutical Technology
ImmunoPrecise Antibodies to Join AI Drug Summit - TipRanks
ImmunoPrecise Sets Virtual AGM for November 2024 - TipRanks
ImmunoPrecise Heralds Nobel Win, AI-Driven Biotherapeutics - TipRanks
ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design - Business Wire
ImmunoPrecise Antibodies Ltd (IPA) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amid ... - Yahoo Finance
Financial Metrics Exploration: Understanding ImmunoPrecise Antibodies Ltd (IPA) Through Ratios - The Dwinnex
ImmunoPrecise Antibodies Ltd (IPA) Stock: A Year of Market Fluctuations - The InvestChronicle
Take off with ImmunoPrecise Antibodies Ltd (IPA): Get ready for trading - SETE News
ImmunoPrecise and Biotheus partner on bispecific antibodies to treat cancer - Yahoo Finance
ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus - BioSpace
ImmunoPrecise Advances Cancer Therapy with Biotheus Partnership - TipRanks
Have you been able to find a good deal on ImmunoPrecise Antibodies Ltd’s shares? - US Post News
ImmunoPrecise Antibodies Ltd (IPA)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
ImmunoPrecise’s Breakthroughs in Cancer Antibody Therapies - TipRanks
ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments - StockTitan
ImmunoPrecise Sets Virtual Annual General Meeting - TipRanks
Ratio Review: Analyzing ImmunoPrecise Antibodies Ltd (IPA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Was ImmunoPrecise Antibodies Ltd (IPA)’s session last reading good? - US Post News
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q1 2025 Earnings Call Transcript - Insider Monkey
ImmunoPrecise Unveils Executive Compensation Strategy - TipRanks
IPA Stock Update: ImmunoPrecise Antibodies Ltd’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
Earnings call: ImmunoPrecise announces mixed Q1 results, eyes future growth - Investing.com Australia
Post-Trade Analysis: ImmunoPrecise Antibodies Ltd (IPA) Slides -19.12, Closing at 0.54 - The Dwinnex
ImmunoPrecise Antibodies Ltd (IPA) Q1 2025 Earnings Call Transcript Highlights: Revenue Growth ... - Yahoo Finance UK
ImmunoPrecise Antibodies Ltd (IPA) Q1 2025 Earnings Call Transcript Highlights: Revenue Growth ... By GuruFocus - Investing.com Canada
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q1 Loss, Misses Revenue Estimates - MSN
ImmunoPrecise Achieves AI-Driven Growth Amidst Challenges - TipRanks
ImmunoPrecise Advances Biotherapeutic Research Efficiency - TipRanks
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 - Business Wire
Earnings To Watch: ImmunoPrecise Antibodies Ltd (IPA) Reports Q1 2025 Result - GuruFocus.com
ImmunoPrecise Announces Upcoming Earnings Call - TipRanks
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024 - Business Wire
ImmunoPrecise Joins Prestigious Global Investment Conference - TipRanks
ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York - Business Wire
ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements - StockTitan
ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology - Chronicle-Tribune
Short Interest in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Declines By 14.4% - Defense World
Benchmark Lowers ImmunoPrecise Antibodies (NASDAQ:IPA) Price Target to $3.00 - Defense World
Immunoprecise shares target cut, rating held on market volatility - Investing.com
Finanzdaten der Immunoprecise Antibodies Ltd-Aktie (IPA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):